Dr. Reddy’s Announces First-to-Market Launch of Generic Bosulif®️ Tablets in the U.S.
Dr. Reddy’s Laboratories Ltd. has launched Bosutinib Tablets 400mg, a first-to-market generic equivalent of Wyeth LLC’s Bosulif®, in the United States. As a first-to-file product,...
Novo Nordisk’s Denecimig shows positive phase 3 results at ISTH 2026
Novo Nordisk announced encouraging interim results from its phase 3 FRONTIER 4 long-term extension study at the International Society on Thrombosis and Haemostasis (ISTH)...
Glenmark Pharmaceuticals Inc., USA Launches Olanzapine for Injection
Glenmark Pharmaceuticals Inc., USA (Glenmark) has announced the official launch of Olanzapine for Injection, 10mg/vial, available as a Single-Dose Vial.
The newly launched product is bioequivalent...
GSK-partnered Hansoh Pharma reports positive Phase III lung cancer data.
GSK plc shared an announcement from its licensor, HansohPharmaceutical Group Co., Ltd., confirming that the pivotal phase III ARTEMIS-008 trial evaluating risvutatug rezetecan(Ris-Rez) met its primary endpoint...
FDA Grants Accelerated Approval to Vera Therapeutics’ TRUTAKNA™️ for Primary IgA Nephropathy
Vera Therapeutics, Inc. (Nasdaq: VERA) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to TRUTAKNA™ (atacicept-vymj). The therapy is...
Enhertu Becomes First HER2 Tumour-Agnostic Therapy Approved in Europe for solid tumours
AstraZeneca and Daiichi Sankyo announced that the European Commission has approved Enhertu (trastuzumab deruxtecan) as a monotherapy for adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumours...
